Articles By Alyson Martin
The FDA has been collecting public comments since April to inform CBD product rules, and the window closes tomorrow. From state ag regulators to New York’s Bar Association, here are some highlights.
On the road to the legislative session’s end, legalization at times seemed certain. But consensus among lawmakers, and support in the Senate, fell short.
The agency, which will determine the future of the CBD industry, also provided an update on its information gathering. And yesterday, Canada’s health officials initiated a somewhat similar process.
Today in Albany, the legislative session draws to a close.
A recent cannabis and opioid study highlighted that “corporate actors” with “deep pockets have substantial ability to promote congenial results, as suffering people are desperate for effective solutions.”
“The objections from members are varied, and for every one we satisfy, another objects,” Sen. Diane Savino told Cannabis Wire.
Messages for and against legalization are popping up across the state as the deadline nears to pass an adult use bill.
Proposed legislation isn’t intended to bypass the FDA’s forthcoming national regulations. But with CBD products already on shelves, lawmakers can’t wait.
"Across the United States, state and local regulators have been confronted with a huge onslaught of CBD.”